Mankind Pharma has received updated credit ratings from ICRA Limited for its various financial instruments. The company saw a reaffirmation of its [ICRA]AA+ (Stable) rating for both long-term fund-based limits and non-convertible debentures. Additionally, ICRA has assigned a new [ICRA]A1+ rating for the company’s commercial paper issuance, reflecting the stable financial standing and creditworthiness of the pharmaceutical firm as of May 12, 2026.
Summary of Credit Ratings
Mankind Pharma Limited has officially announced the receipt of updated credit ratings from the rating agency ICRA Limited. The reaffirmation of the company’s existing ratings highlights a consistent financial profile and strong debt management capabilities. The current ratings for the company’s key instruments remain in the high-grade category, reinforcing investor confidence.
Breakdown of Instrument Ratings
The rating agency evaluated several key financial instruments as follows:
- Long-term/Short-term fund-based limits: Reaffirmed at [ICRA]AA+ (Stable) / [ICRA]A1+ for an amount of ₹1,250 crore.
- Non-convertible Debentures: Reaffirmed at [ICRA]AA+ (Stable) for an amount of ₹5,000 crore.
- Commercial Paper: Assigned a new rating of [ICRA]A1+ for an amount of ₹600 crore.
Strategic Financial Standing
The assignment of the [ICRA]A1+ rating for commercial paper, alongside the sustained AA+ ratings for long-term facilities, underscores the company’s robust liquidity position. These credit ratings are essential for the company’s ongoing capital management and demonstrate its ability to meet short-term and long-term financial obligations effectively as it continues its operations in the pharmaceutical sector.
Source: BSE
